COVID-19 pandemic shifted epidemiology for cancer screening sites: breast, cervix, colon, and rectum.

IF 3.5 3区医学 Q2 ONCOLOGY Frontiers in Oncology Pub Date : 2025-01-30 eCollection Date: 2024-01-01 DOI:10.3389/fonc.2024.1481242

Yevgeniy Ishkinin, Dilyara Kaidarova, Serzhan Nazarbek, Alma Zhylkaidarova, Saniya Ossikbayeva, Kamilla Mussina, Nazgul Omarbayeva

{"title":"COVID-19 pandemic shifted epidemiology for cancer screening sites: breast, cervix, colon, and rectum.","authors":"Yevgeniy Ishkinin, Dilyara Kaidarova, Serzhan Nazarbek, Alma Zhylkaidarova, Saniya Ossikbayeva, Kamilla Mussina, Nazgul Omarbayeva","doi":"10.3389/fonc.2024.1481242","DOIUrl":null,"url":null,"abstract":"Background: This study aimed to assess the epidemiological changes in breast, cervical, colon, and rectal cancers in Kazakhstan before and during COVID-19, including early-onset cancer (EOC) diagnosed between the ages of 20 and 49, using data from the oncological service of the Republic of Kazakhstan for the 2017-2022 period.Methods: The cohort comprised patients aged 20 to 49 years (EOC) and 50 years and older [late-onset cancer (LOC)] from the total number of patients diagnosed each year during the study period of 2017 to 2022 for breast, cervical, colon, or rectal cancer. In order to indicate a difference in one-time intervals and characterize the global trend over the entire study period, annual percentage change (APC) and average APC (AAPC) were calculated, respectively.Results: Breast cancer detection rates increased by 22.8% for EOC and 15.9% for LOC from 2017 to 2022, and AAPC increased by 4.3% for EOC and 3.6% for LOC. During the COVID-19 restriction period, breast cancer detection rates decreased by 6.1% for EOC and 15.6% for LOC. Cervical cancer detection rates increased by 2.3% for EOC and 7.5% for LOC from 2017 to 2022, and AAPC increased by 0.9% for EOC and 1.6% for LOC. During the COVID-19 restriction period, cervical cancer detection rates decreased by 11.3% for EOC and 3.1% for LOC. Colon cancer detection rates increased by 18.4% for EOC and 14.3% for LOC from 2017 to 2022, and AAPC increased by 3.7% for EOC and 2.9% for LOC. During the COVID-19 restriction period, colon cancer detection rates decreased by 14.4% for EOC and 5.8% for LOC. Rectal cancer detection rates increased by 13.6% for EOC and 19.2% for LOC from 2017 to 2022, and AAPC increased by 3.0% for EOC and by 3.9% for LOC. During the COVID-19 restriction period, rectal cancer detection rates increased by 18.6% for EOC and decreased by 12.0% for LOC.Conclusion: The epidemiological indicators of population cancer screening worsened during the COVID pandemic; the detection rate decreased by 6.1% for breast EOC and 11.3% for cervical EOC, while there was an increase by 38.0% in EOC for colon cancer in men and by 8.0% in EOC for rectal cancer in men and 31.1% in women.","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1481242"},"PeriodicalIF":3.5000,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11822355/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fonc.2024.1481242","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This study aimed to assess the epidemiological changes in breast, cervical, colon, and rectal cancers in Kazakhstan before and during COVID-19, including early-onset cancer (EOC) diagnosed between the ages of 20 and 49, using data from the oncological service of the Republic of Kazakhstan for the 2017-2022 period.

Methods: The cohort comprised patients aged 20 to 49 years (EOC) and 50 years and older [late-onset cancer (LOC)] from the total number of patients diagnosed each year during the study period of 2017 to 2022 for breast, cervical, colon, or rectal cancer. In order to indicate a difference in one-time intervals and characterize the global trend over the entire study period, annual percentage change (APC) and average APC (AAPC) were calculated, respectively.

Results: Breast cancer detection rates increased by 22.8% for EOC and 15.9% for LOC from 2017 to 2022, and AAPC increased by 4.3% for EOC and 3.6% for LOC. During the COVID-19 restriction period, breast cancer detection rates decreased by 6.1% for EOC and 15.6% for LOC. Cervical cancer detection rates increased by 2.3% for EOC and 7.5% for LOC from 2017 to 2022, and AAPC increased by 0.9% for EOC and 1.6% for LOC. During the COVID-19 restriction period, cervical cancer detection rates decreased by 11.3% for EOC and 3.1% for LOC. Colon cancer detection rates increased by 18.4% for EOC and 14.3% for LOC from 2017 to 2022, and AAPC increased by 3.7% for EOC and 2.9% for LOC. During the COVID-19 restriction period, colon cancer detection rates decreased by 14.4% for EOC and 5.8% for LOC. Rectal cancer detection rates increased by 13.6% for EOC and 19.2% for LOC from 2017 to 2022, and AAPC increased by 3.0% for EOC and by 3.9% for LOC. During the COVID-19 restriction period, rectal cancer detection rates increased by 18.6% for EOC and decreased by 12.0% for LOC.

Conclusion: The epidemiological indicators of population cancer screening worsened during the COVID pandemic; the detection rate decreased by 6.1% for breast EOC and 11.3% for cervical EOC, while there was an increase by 38.0% in EOC for colon cancer in men and by 8.0% in EOC for rectal cancer in men and 31.1% in women.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

COVID-19大流行改变了癌症筛查部位的流行病学：乳腺癌、宫颈癌、结肠癌和直肠。

背景：本研究旨在利用哈萨克斯坦共和国肿瘤服务部门2017-2022年期间的数据，评估2019冠状病毒病之前和期间哈萨克斯坦乳腺癌、宫颈癌、结肠癌和直肠癌的流行病学变化，包括20至49岁之间诊断的早发性癌症（EOC）。方法：该队列包括2017年至2022年研究期间每年诊断的乳腺癌、宫颈癌、结肠癌或直肠癌患者总数中年龄在20至49岁（EOC）和50岁及以上的[晚发性癌症（LOC）]患者。为了表明一次间隔的差异并表征整个研究期间的全球趋势，分别计算了年百分比变化（APC）和平均APC （AAPC）。结果：2017 - 2022年，乳腺癌EOC检出率上升22.8%，LOC检出率上升15.9%，AAPC在EOC和LOC中分别上升4.3%和3.6%。在COVID-19限制期间，EOC和LOC的乳腺癌检出率分别下降了6.1%和15.6%。从2017年到2022年，宫颈癌的检出率分别上升了2.3%和7.5%，宫颈癌的AAPC分别上升了0.9%和1.6%。在COVID-19限制期间，EOC和LOC的宫颈癌检出率分别下降了11.3%和3.1%。从2017年到2022年，结肠癌EOC的检出率上升了18.4%，LOC的检出率上升了14.3%，AAPC在EOC和LOC中分别上升了3.7%和2.9%。在COVID-19限制期间，EOC和LOC的结肠癌检出率分别下降了14.4%和5.8%。2017年至2022年，直肠癌EOC的检出率上升了13.6%，LOC的检出率上升了19.2%，AAPC在EOC和LOC中分别上升了3.0%和3.9%。在COVID-19限制期间，EOC的直肠癌检出率上升18.6%，LOC的检出率下降12.0%。结论：新冠肺炎疫情期间人群癌症筛查流行病学指标恶化；乳腺癌和宫颈癌的检出率分别下降了6.1%和11.3%，而男性结肠癌、男性直肠癌和女性的检出率分别上升了38.0%、8.0%和31.1%。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Frontiers in Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

6.20

自引率

10.60%

发文量

6641

审稿时长

14 weeks

期刊介绍： Cancer Imaging and Diagnosis is dedicated to the publication of results from clinical and research studies applied to cancer diagnosis and treatment. The section aims to publish studies from the entire field of cancer imaging: results from routine use of clinical imaging in both radiology and nuclear medicine, results from clinical trials, experimental molecular imaging in humans and small animals, research on new contrast agents in CT, MRI, ultrasound, publication of new technical applications and processing algorithms to improve the standardization of quantitative imaging and image guided interventions for the diagnosis and treatment of cancer.